Skip to content

Cangrelor

FDA-approved product (powder, intravenous), marketed as Cangrelor, Kengreal.

Registered studies
45
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cangrelor
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Myocardial infarction
  • Percutaneous Coronary Intervention
  • Recurrent thrombophlebitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Platelet aggregation inhibitors excl. heparin
FDA pharmacologic class
P2Y12 Platelet Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli45.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis44.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

45registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cangrelor with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Cangrelor Neonatal PK/PD and Safety Study

    NCT02765633 · start 2017-01-03

    Registered record
    Registry ID
    NCT02765633
    Conditions
    Partial Obstruction of Systemic to Pulmonary Artery Shunt; Complete Obstruction of Systemic to Pulmonary Artery Shunt
    Interventions
    Cangrelor
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-01-03
    Completion
    2019-12-23
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPartial Obstruction of Systemic to Pulmonary Artery Shunt; Complete Obstruction of Systemic to Pulmonary Artery Shunt
    InterventionCangrelor
    PhasePhase 1
    Registry statusCompleted
  • Cangrelor in ST-Elevation Myocardial Infarction to Decrease Infarct Size

    NCT03043274 · start 2017-01

    Registered record
    Registry ID
    NCT03043274
    Conditions
    STEMI - ST Elevation Myocardial Infarction
    Interventions
    Cangrelor
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2017-01
    Completion
    2019-05
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSTEMI - ST Elevation Myocardial Infarction
    InterventionCangrelor
    PhasePhase 4
    Registry statusTerminated
  • The Effect of IV Cangrelor and Oral Ticagrelor Study

    NCT02733341 · start 2016-07-21

    Registered record
    Registry ID
    NCT02733341
    Conditions
    Acute Coronary Syndrome (ACS); High On-treatment Platelet Reactivity (HTPR); Microvascular Obstruction (MVO); ST-segment Elevation Myocardial Infarction (STEMI); Thrombolysis in Myocardial Infarction (TIMI); Unstable Angina (UA)
    Interventions
    Cangrelor; Ticagrelor
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-07-21
    Completion
    2018-10-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome (ACS); High On-treatment Platelet Reactivity (HTPR); Microvascular Obstruction (MVO); ST-segment Elevation Myocardial Infarction (STEMI) +2 more
    InterventionCangrelor; Ticagrelor
    PhasePhase 4
    Registry statusCompleted
  • Platelet Function in Resuscitated Patients-2

    NCT03445546 · start 2016-05-01

    Registered record
    Registry ID
    NCT03445546
    Conditions
    Acute Myocardial Infarction; Cardiac Arrest
    Interventions
    diagnostic test of platelet function
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-05-01
    Completion
    2018-05-15
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myocardial Infarction; Cardiac Arrest
    Interventiondiagnostic test of platelet function
    PhaseNot recorded
    Registry statusCompleted
  • In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients

    NCT02081443 · start 2014-04

    Registered record
    Registry ID
    NCT02081443
    Conditions
    Coronary Artery Disease
    Interventions
    Ticagrelor 180mg; Ticagrelor 90mg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-04
    Completion
    2015-10
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionTicagrelor 180mg; Ticagrelor 90mg
    PhaseNot applicable
    Registry statusCompleted
  • Cangrelor to Clopidogrel or Prasugrel Transition Study

    NCT01979445 · start 2013-12-02

    Registered record
    Registry ID
    NCT01979445
    Conditions
    Coronary Artery Disease (CAD)
    Interventions
    Cangrelor; Clopidogrel; Prasugrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-12-02
    Completion
    2014-01-20
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease (CAD)
    InterventionCangrelor; Clopidogrel; Prasugrel
    PhasePhase 2
    Registry statusCompleted
  • Cangrelor Prasugrel Transition Study

    NCT01852019 · start 2013-06

    Registered record
    Registry ID
    NCT01852019
    Conditions
    Coronary Artery Disease
    Interventions
    Cangrelor; Prasugrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-06
    Completion
    2013-07
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionCangrelor; Prasugrel
    PhasePhase 2
    Registry statusCompleted
  • Cangrelor Ticagrelor Transition Study

    NCT01766466 · start 2013-01

    Registered record
    Registry ID
    NCT01766466
    Conditions
    Coronary Artery Disease
    Interventions
    cangrelor; Ticagrelor
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-01
    Completion
    2013-02
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    Interventioncangrelor; Ticagrelor
    PhasePhase 2
    Registry statusCompleted
  • A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)

    NCT01156571 · start 2010-09

    Registered record
    Registry ID
    NCT01156571
    Conditions
    Atherosclerosis; Percutaneous Coronary Intervention; Acute Coronary Syndrome
    Interventions
    cangrelor P2Y12 (platelet) inhibitor; Clopidogrel - 300 or 600 mg (study arm); Clopidogrel 600 mg post cangrelor
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-09
    Completion
    2012-12
    Enrolment
    11,145

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtherosclerosis; Percutaneous Coronary Intervention; Acute Coronary Syndrome
    Interventioncangrelor P2Y12 (platelet) inhibitor; Clopidogrel - 300 or 600 mg (study arm); Clopidogrel 600 mg post cangrelor
    PhasePhase 3
    Registry statusCompleted
  • Maintenance of Platelet Inhibition With Cangrelor

    NCT00767507 · start 2008-10

    Registered record
    Registry ID
    NCT00767507
    Conditions
    Acute Coronary Syndrome (ACS)
    Interventions
    cangrelor; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-10
    Completion
    2011-07
    Enrolment
    221

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome (ACS)
    Interventioncangrelor; Placebo
    PhasePhase 2
    Registry statusCompleted
  • Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers

    NCT00699504 · start 2008-06

    Registered record
    Registry ID
    NCT00699504
    Conditions
    Healthy
    Interventions
    cangrelor; cangrelor; cangrelor; moxifloxacin; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-06
    Completion
    2008-11
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventioncangrelor; cangrelor; cangrelor; moxifloxacin +1 more
    PhasePhase 1
    Registry statusCompleted
  • Aspirin Resistance and Percutaneous Coronary Intervention (PCI)

    NCT01103440 · start 2007-04

    Registered record
    Registry ID
    NCT01103440
    Conditions
    Stable Angina
    Interventions
    Intravenous Glycoprotein inhibitor + ASA, Clopidogrel; Antiplatelet Therapy (ASA, Clopidogrel)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-04
    Completion
    2009-06
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStable Angina
    InterventionIntravenous Glycoprotein inhibitor + ASA, Clopidogrel; Antiplatelet Therapy (ASA, Clopidogrel)
    PhasePhase 2
    Registry statusCompleted
  • Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

    NCT00385138 · start 2006-09

    Registered record
    Registry ID
    NCT00385138
    Conditions
    Atherosclerosis; Acute Coronary Syndrome (ACS)
    Interventions
    Cangrelor; clopidogrel; Placebo bolus & placebo infusion; Placebo capsules - end of PCI; Placebo capsules - end of infusion
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2006-09
    Completion
    2010-06
    Enrolment
    5,364

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtherosclerosis; Acute Coronary Syndrome (ACS)
    InterventionCangrelor; clopidogrel; Placebo bolus & placebo infusion; Placebo capsules - end of PCI +1 more
    PhasePhase 3
    Registry statusTerminated
  • A Clinical Trial to Demonstrate the Efficacy of Cangrelor

    NCT00305162 · start 2006-04

    Registered record
    Registry ID
    NCT00305162
    Conditions
    Myocardial Infarction (MI); Acute Coronary Syndromes (ACS)
    Interventions
    Cangrelor (P2Y12 inhibitor); clopidogrel (oral P2Y12 inhibitor); Placebo bolus & placebo infusion; Placebo capsules - end of infusion; Placebo capsules - as soon as possible after randomization
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2006-04
    Completion
    2010-06
    Enrolment
    8,882

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Infarction (MI); Acute Coronary Syndromes (ACS)
    InterventionCangrelor (P2Y12 inhibitor); clopidogrel (oral P2Y12 inhibitor); Placebo bolus & placebo infusion; Placebo capsules - end of infusion +1 more
    PhasePhase 3
    Registry statusTerminated
  • Pharmacokinetics/Pharmacodynamics (PK/PD) of Cangrelor

    NCT00102674 · start 2005-03

    Registered record
    Registry ID
    NCT00102674
    Conditions
    Healthy
    Interventions
    cangrelor
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-03
    Completion
    2005-05
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventioncangrelor
    PhasePhase 1
    Registry statusCompleted